Therapeutic Goods Regulations (Amendment)

Overview

The Therapeutic Goods Regulations (Amendment) 1984, issued under the authority of the Minister for Health, address a legislative gap concerning the regulation of therapeutic goods used for pregnancy testing and contraception, as well as the requirement for prescribed corporations to provide information about these goods. Enacted by the Parliament of Australia, the policy objective of this amendment is to align the Therapeutic Goods Act 1986 with the establishment of the National Register of Therapeutic Goods, as initiated by the Health Acts Amendment Act 1981. This amendment ensures that the necessary therapeutic goods are included in the National Register and mandates that corporations supply detailed information about these goods to facilitate effective oversight and public safety.

Scope and Application

The Therapeutic Goods Regulations (Amendment) Statutory Rules 1984 No. 53, made under the Therapeutic Goods Act 1966, extend the application of the Act to include certain therapeutic goods used for pregnancy testing and contraception, aligning with the legislative changes introduced by the Health Acts Amendment Act 1981. These regulations specifically declare that goods used for pregnancy testing and contraception are therapeutic goods to which the Act applies, thereby including them in the regulatory framework established by the Act. Additionally, the regulations provide for the establishment of the National Register of Therapeutic Goods by prescribing detailed information that must be furnished by corporations that supply or produce therapeutic goods in Australia. This includes substances, such as pharmaceutical preparations, which must be declared in the Regulations to enable the supply of information for the National Register. Notably, these therapeutic goods are subject to specific exclusions, such as homeopathic goods, certain in vitro diagnostic goods, and goods used as ingredients or in the preparation of other therapeutic substances. The information prescribed under these regulations encompasses a comprehensive set of details about the therapeutic goods, including proprietary and non-proprietary names, manufacturer and quality control details, active substance content, dosage forms, and labelling information, ensuring a thorough and standardised approach to the regulation of therapeutic goods in Australia.

Key Provisions

The key provisions of the Therapeutic Goods Regulations (Amendment) (Statutory Rules 1984 No. 53) pertain primarily to the declaration of certain therapeutic goods and the information requirements for these goods. Section 4A declares that therapeutic goods used for pregnancy testing and contraception are goods to which the Therapeutic Goods Act 1966 (the Act) applies. This declaration ensures that these goods are subject to the regulatory framework established by the Act, including registration and monitoring requirements. Regulation 4B further specifies that goods for therapeutic use that consist of a substance, excluding certain exceptions such as homeopathic goods and diagnostic goods for in vitro use other than for diagnosing pregnancy, are also declared to be goods to which section 23M of the Act applies. This inclusion broadens the scope of substances subject to the Act, ensuring that more therapeutic goods are subject to regulatory oversight. Under regulation 4C, detailed information requirements are prescribed for therapeutic goods to be provided for the purposes of the Act. This includes the proprietary name, manufacturer details, identity and address of the person responsible for quality and safety, non-proprietary names of substances, active substance content, dosage form, route of administration, labelling details, and accompanying explanatory material. These requirements ensure that comprehensive information about the therapeutic goods is available, facilitating better regulation and consumer protection. The obligations imposed by the Act and these regulations on parties and entities include the necessity to provide detailed information about therapeutic goods, particularly those that consist of a substance. Entities must ensure that the prescribed information is accurate and complete, as mandated by regulation 4C. Compliance with these information requirements is critical for the registration and ongoing monitoring of therapeutic goods under the National Register of Therapeutic Goods. Failure to comply with the obligations and requirements set forth by the Act and the regulations can lead to significant consequences. Breaches may result in enforcement actions, including civil or criminal penalties. While the specific penalties are not detailed in the regulations, they can include fines and other sanctions that reflect the severity of the non-compliance. It is important for entities to adhere strictly to the information requirements to avoid any legal repercussions.